A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subject with treatment-resistant depression in the course of Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Celon Pharma
- 04 Nov 2019 Planned End Date changed from 1 Oct 2019 to 1 Jan 2020.
- 04 Nov 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Nov 2019.
- 06 Sep 2018 New trial record